ESCALON MEDICAL CORP (ESMC) Form 10-K — Oct 13, 2026
Escalon Medical reported fiscal 2026 revenue of $12.74 million, up 5.7% year over year, driven by a $1.26 million increase in Sonomed sales that offset declines in Trek and AXIS. Net income was $4.01 million ($0.27 per basic share), but this was overwhelmingly driven by a $2.81 million pre-tax gain on the sale of the AXIS software business (which fetched $3.0 million, $2.8 million net) plus a $1.14 million deferred tax benefit; income from continuing operations was only about $45,000. Liquidity improved markedly, with cash rising to $3.07 million and working capital to $4.62 million (current ratio 2.94x), largely due to the AXIS sale proceeds.
Key figures
- Eps
- 0.27
- Revenue
- 12736145
- Net Income
- 4012626
- Total Debt
- 975000
- Revenue Yoy
- 5.7%
- Total Assets
- 9128115
- Cash Position
- 3065468
- Shares Outstanding
- 7415329
- Employees
- 40
- Gross margin
- 43.7%
- Current ratio
- 2.94 to 1
- Axis sale gain
- 2813525
- Axis sale price
- 3000000
- Working capital
- 4624000
- Axis net proceeds
- 2800000
- Valuation allowance release
- 1139449
- Otc closing price oct 9 2026
- 0.15
- Income from continuing operations fy2026
- 45235
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.